- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2020-06-15
2022-10-07
2022-11-30
244
NCT04400357
Ruijin Hospital
Ruijin Hospital
INTERVENTIONAL
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
The PORTAL trial is a Phase 3 multicenter non-inferiority randomized controlled trial that aims to address the question of feasibility and efficacy of the robotic minimally invasive approach in pancreaticoduodenectomy. In the past 10 years there has been an increasing number of retrospective series from major centers for pancreatic surgery worldwide, that demonstrate similar and occasionally improved postoperative outcomes in patients who undergo a robotic pancreaticoduodenectomy (Whipple). The benefits of this minimally invasive approach appear to be decreased intraoperative estimated blood loss, lower postoperative pain levels and smaller length of hospital stay, whereas postoperative complications rates are comparable with the standard open approach. This trial is conducted in multiple major centers for pancreatic surgery (open and robotic) in China and aims to address these questions in a prospective fashion. All eligible patients who present to these centers within the study period will be randomized in a 1:1 ratio to either of the two arms (open vs. robotic). Patients enrolled in the study will be blinded regarding the type of the procedure by application of identical wound dressings at the trocar sites and the open incision. Patients will be followed up closely and will be evaluated routinely for quality of life parameters for a period of at least 2 years postoperatively. Additionally, patients who undergo surgery in either arm for pancreatic adenocarcinoma will also be evaluated for time to adjuvant chemotherapy postoperatively, as well as recurrence and survival data.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2020-05-10 | N/A | 2022-04-30 |
2020-05-20 | N/A | 2022-05-03 |
2020-05-22 | N/A | 2022-04 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Treatment
Allocation:
Randomized
Interventional Model:
Parallel
Masking:
Single
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: Robotic pancreaticoduodenectomy Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy. | PROCEDURE: Robotic pancreaticoduodenectomy
|
| ACTIVE_COMPARATOR: Open pancreaticoduodenectomy Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy. | PROCEDURE: Open pancreaticoduodenectomy
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Time to functional recovery postoperatively | Daily evaluation of patient postoperative course will take place by the nursing and medical staff and will be documented by the study coordinators. Postoperative criteria that need to be fulfilled independently to achieve functional recovery status are the following: * Discontinuation of intravenous or subcutaneous analgesia and preservation of adequate control levels (pain score) * Early ambulation and restoration of mobility to an independent level (or to preoperative level if previously impaired) * Ability to maintain sufficient oral caloric intake as defined by institutional dietitian services, without intravenous fluid support * No clinical signs of active abdominal infection affecting the patient's performance status: absence of fever, white cell count and C-reactive protein decreasing towards normalization. The patient can be in oral antibiotics. | From date of surgery to date of functional recovery as described, assessed up to 90 days. |
| Percentage of patients with pancreatic adenocarcinoma who achieve administration of adjuvant chemotherapy at 8 weeks postoperatively | The number of patients who are fit and well to initiate adjuvant chemotherapy at the 8-week mark after the operation will be documented and compared between the two arms | Postoperative Day 1 to Day 56 |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Intraoperative blood loss | Comparison of estimated blood loss (in ml) | During surgery |
| Operative time | Comparison of operative time (in minutes, from first incision to skin closure) | During surgery |
| Postoperative complication rates and associated interventions | Comparison of post-pancreatectomy morbidity between the two surgical approaches, that focus on: * Pancreatic fistula * Bile leak * Chyle leak * Delayed gastric emptying * Surgical site infection * Postoperative pancreatitis * Postoperative hemorrhage * Surgical site infections * Other complications Additional documentation of re-intervention (radiological, endoscopic, or surgical) and re-admission rates, as well as postoperative hospital and ICU length of stay (time to discharge) | Postoperative Day 1 to Day 30 |
| Postoperative mortality | Comparison of mortality rates as a result of the pancreaticoduodenectomy in each arm | Postoperative Day 1 to Day 90 |
| Quality of life measurements | For assessment of postoperative quality of life (QoL) improvement, patients will be evaluated with the established EuqoQol EQ-5D-5L questionnaire, which is a self-reported assay focusing on five parameters: Pain/discomfort, anxiety/depression, usual activities, self-care, and mobility. Each of the five aforementioned parameters is scored from 0 to 5 (no issue, slight problem, moderate problem, severe problem, unable); patients also score independently their health status on a scale numbered from 0 to 100; 100 means the best health they can imagine, and 0 the worst. Answered questionnaires will be collected on postoperative days 1, 3, 5, 7, and afterwards every week until day 30. QoL evaluation will terminate at Day 90. | Postoperative Day 1 to Day 90 |
| Margin resection status (R) in patients with pancreatic adenocarcinoma | In a sub-cohort of patients with pancreatic adenocarcinoma, the margin resection status (R) will be assessed and compared: R0 is defined as presence of tumor >1mm from the resection margin, R1 as presence of tumor ≤1mm from the resection margin. * Number of harvested lymph nodes * Number of positive lymph nodes (infiltrated by tumor) * Tumor size, degree of differentiation, perineural and lymphovascular invasion | During surgery |
| Differences in locoregional lymphadenectomy in patients with pancreatic adenocarcinoma | In a sub-cohort of patients with pancreatic adenocarcinoma, the number of harvested and positive lymph nodes (infiltrated by tumor) will be assessed and compared between the two groups. | During surgery |
| Postoperative recurrence in patients with pancreatic adenocarcinoma | Patients with pancreatic adenocarcinoma who undergo resection in each arm will be followed postoperatively to document disease recurrence, defined as the re-presentation of measurable tumor after resection. | Postoperative Day 1 up to 5 years after surgery |
| Postoperative survival in patients with pancreatic adenocarcinoma | Patients with pancreatic adenocarcinoma who undergo resection in each arm will be followed postoperatively to document overall survival, defined as the time between date of operation and date of death. | Postoperative Day 1 up to 5 years after surgery |
| Perioperative costs | Comparison of cost between the two groups, defined as the combination of intraoperative and postoperative costs, measured in US Dollars. | Postoperative Day 1 to Day 90 |
| Effect of operative approach on circulating biomarkers in the postoperative setting | Enrolled patients in the study will be consented for peripheral blood draws in multiple time-points to assess the amount of circulating tumor DNA (ctDNA) and assess potential differences between the two groups in patients with pancreatic adenocarcinoma. The blood draws will occur: 1. immediately pre-operatively, 2. Postoperative days 2, 7, and 30. | Postoperative Day 1 to Day 30 |
| Comparison of perioperative inflammatory response (C-reactive protein) | Patients C-reactive protein (CRP, measured in ng/L) will be assessed with peripheral blood draws on the day of operation, and postoperative days 1, 3, and 7. | Day of surgery to Postoperative Day 7 |
| Comparison of perioperative inflammatory response (Neutrophil-to-Lymphocyte ratio) | Patients neutrophil-to-lymphocyte ratio (NLR, defined as the division of absolute neutrophil number to absolute lymphocyte number) will be assessed with peripheral blood draws on the day of operation, and postoperative days 1, 3, and 7. | Day of surgery to Postoperative Day 7 |
| Comparison of perioperative inflammatory response (Interleukin-6) | Patients Interleukin 6 (IL-6, measured in pg/mL) will be assessed with peripheral blood draws on the day of operation, and postoperative days 1, 3, and 7. | Day of surgery to Postoperative Day 7 |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Jiabin JIN, PhD Phone Number: 008618101870031 Email: jjb11501@rjh.com.cn |
Study Contact Backup Name: Georgios Gemenetzis, MD Phone Number: Email: georgios.gemenetzis@glasgow.ac.uk |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
